05.19.22
Colin Hill, PhD, DSc, recently was appointed by pharmaceutical, nutraceutical, and food products ingredient supplier Kyowa Hakko to join the scientific advisory board for its postbiotic ingredient, Immuse.
Immuse is supported by 29 published studies which evidence its activating role in supporting healthy immune function, and its mechanism of action is believed to be the activation of pDC (plasmacytoid dendritic cells). This type of immune cell functions to activate NK, Killer-T, Helper-T, and B cells.
Hill will work to further advance the understanding and education surrounding postbiotics, as defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP). Hill will participate in group discussions as a postbiotic expert and provide scientific group evaluation and feedback. This is in line with Kyowa Hakko’s strategy to have world-class experts disseminate complex information about various ingredients, according to the company.
“We are privileged to have someone with such extensive knowledge and expertise on postbiotics join us to add his uniquely scientific perspective to our work with Immuse,” said Karen Todd, MBA, RD, vice president of global brand marketing for Kyowa Hakko. “Dr. Hill will help lead Kyowa Hakko’s future efforts in postbiotics.”
Hill served on the ISAPP board of directors since 2009, and was president from 2012-2015. He was the lead author on ISAPP’s consensus paper on postbiotics, participated in the ISAPP consensus panel on postbiotics, led numerous ISAPP discussion groups during its annual meetings, and co-authored 10 of the organization’s publications.
“We are very much looking forward to working with Dr. Hill as we are only beginning to discover the opportunities that postbiotics hold for human health,” Todd said.
Hill will be joining Nutraceuticals World to take part in a webinar, titled “A Postbiotic with Unmatched Clinical Research – Immuse LC-Plasma: An Innovative Approach to Immune Health” on Tuesday, May 31 at 11:00 a.m. EDT. To attend this free webinar, sponsored by Kyowa Hakko, register here.
Immuse is supported by 29 published studies which evidence its activating role in supporting healthy immune function, and its mechanism of action is believed to be the activation of pDC (plasmacytoid dendritic cells). This type of immune cell functions to activate NK, Killer-T, Helper-T, and B cells.
Hill will work to further advance the understanding and education surrounding postbiotics, as defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP). Hill will participate in group discussions as a postbiotic expert and provide scientific group evaluation and feedback. This is in line with Kyowa Hakko’s strategy to have world-class experts disseminate complex information about various ingredients, according to the company.
“We are privileged to have someone with such extensive knowledge and expertise on postbiotics join us to add his uniquely scientific perspective to our work with Immuse,” said Karen Todd, MBA, RD, vice president of global brand marketing for Kyowa Hakko. “Dr. Hill will help lead Kyowa Hakko’s future efforts in postbiotics.”
Hill served on the ISAPP board of directors since 2009, and was president from 2012-2015. He was the lead author on ISAPP’s consensus paper on postbiotics, participated in the ISAPP consensus panel on postbiotics, led numerous ISAPP discussion groups during its annual meetings, and co-authored 10 of the organization’s publications.
“We are very much looking forward to working with Dr. Hill as we are only beginning to discover the opportunities that postbiotics hold for human health,” Todd said.
Hill will be joining Nutraceuticals World to take part in a webinar, titled “A Postbiotic with Unmatched Clinical Research – Immuse LC-Plasma: An Innovative Approach to Immune Health” on Tuesday, May 31 at 11:00 a.m. EDT. To attend this free webinar, sponsored by Kyowa Hakko, register here.
